Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514577 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
- 15
- Study locations
NCT02514577: Completed Phase 3 study of Plaque Psoriasis, sponsored by Bausch Health Americas.
NCT02514577 is a Phase 3 study of Plaque Psoriasis that has completed, run by Bausch Health Americas. The registered enrollment target is 217 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (47% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02514577, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Primary Outcome
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
Conditions Studied
Interventions
- DRUG IDP-122 Lotion
- DRUG IDP-122 Vehicle Lotion
Study Locations (15)
California
- Valeant Site 1 - Encinitas
- Valeant Site 10 - Encino
- Valeant Site 12 - Santa Rosa
Michigan
- Valeant Site 4 - Ann Arbor
- Valeant Site 8 - Clarkston
Texas
- Valeant Site 3 - Austin
- Valeant Site 2 - San Antonio
Arkansas
- Valeant Site 11 - Hot Springs
Georgia
- Valeant Site 13 - Atlanta
Idaho
- Valeant Site 7 - Boise
Maryland
- Valeant Site 6 - Rockville
Nevada
- Valeant Site 15 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2015-11-07 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 3 |
What the finished NCT02514577 record still lists
NCT02514577 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which IDP-122 Lotion is the first listed.
NCT02514577 lists 15 locations in 11 states (California, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT02514577 about?
NCT02514577 is a clinical study titled "Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis". This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
What is the current status of trial NCT02514577?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2015-11-07. Estimated completion is 2017-05-01.
What conditions does trial NCT02514577 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02514577?
The interventions under investigation include: IDP-122 Lotion (DRUG), IDP-122 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT02514577?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02514577 being conducted?
This trial has 15 study locations across Arkansas, California, Georgia, Idaho, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02514577's enrollment target sits among peer trials
217 21st of 45 higher than 25 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI